EICHOR
● Recruiting
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Condition: Non-Small Cell Lung Cancer (NSCLC) · Sponsor: Shanghai Chest Hospital
About this study
This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) 21-L858R mutations. This study comprises two parts: 1. A dose escalation Phase I study to determine the recommended phase II dose. 2. a multi-center, open label, randomized controlled, Phase IIB study.
This description comes directly from the study's public registry record.
Talk to the study team
Bo Zhang, MD · 15800386291 · zb1063253078@163.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.